Executive brief
Life sciences cybersecurity no longer stops at the enterprise boundary. As pharmaceutical, biotech, and medical device organizations rely on a growing network of software vendors, service providers, AI platforms, and cloud partners, third-party risk has become part of the compliance and inspection conversation.
That shift matters because regulators are not treating vendor oversight as optional. FDA expectations, EMA scrutiny, and emerging frameworks such as NIS2 are pushing organizations to prove that cybersecurity, supplier governance, and compliance controls work together. Annual assessments and static questionnaires are not enough for a regulated environment that changes continuously.
Many organizations still run third-party risk programs designed for a much simpler operating model. Those programs often rely on point-in-time reviews, siloed cybersecurity assessments, and reactive follow-up once a risk is already visible.
In practice, that creates gaps across the partner ecosystem. Teams may lack real-time visibility into vendor posture, rely too heavily on fragmented evidence, or struggle to connect cybersecurity findings to quality and compliance decisions. In a regulated environment, those gaps can show up during audits and inspections.
A stronger life sciences cybersecurity model treats vendor oversight as an ongoing operating capability, not a once-a-year checklist. It combines security intelligence, qualification rigor, compliance context, and continuous monitoring so teams can make better decisions faster.
Integrated evaluation across cybersecurity, compliance, quality, and operational risk
A scalable partner ecosystem requires a repeatable operating model. One effective framework is: